Abstract
BACKGROUND:
Ketorolac's efficacy as a postoperative analgesic has been shown to be comparable to that of narcotic analgesics, but with significantly fewer narcotic-related adverse events.
OBJECTIVE:
To assess whether the choice of postoperative analgesic, narcotic or ketorolac, has an impact on healthcare resource utilization and cost during inpatients' recovery period.
DESIGN:
Retrospective, multicenter, controlled, parallel, cost-minimization analysis.
SETTING:
Six US teaching hospitals.
PATIENTS:
This study included 559 patients that underwent either a spine or joint procedure and received adequate doses of narcotic (n = 284 of either morphine or meperidine) or ketorolac (n = 275).
MEASUREMENTS:
Time to reach recovery milestones, average utilization of healthcare resources, and average per-case postoperative treatment cost.
RESULTS:
Several recovery milestones, including time to first bowel movement, first oral intake, and first unassisted ambulation, were reached sooner in the ketorolac group, with a resultant shorter mean length of postoperative stay (narcotic 3.78 d, ketorolac 2.80 d; p = 0.01). Total per-patient cost of treatment was 32% greater in the narcotic group, resulting primarily from higher costs associated with hospitalization.
CONCLUSIONS:
Despite the higher acquisition cost of medication, healthcare resource utilization and total per-patient cost of treatment were lower for patients in the ketorolac group compared with patients in the narcotic analgesic study group. The majority of patients in the ketorolac group were also given concurrent narcotic analgesics; therefore, the beneficial effects observed may be secondary to the combination of ketorolac and narcotic analgesics.
TRASFONDO:
La eficacia de ketorolac como agente analgésico postoperatorio se ha demostrado que es comparable a la de los analgésicos narcóticos pero con significativamente menos eventos adversos relacionados con el efecto narcótico.
Get full access to this article
View all access options for this article.